On this page
What body-composition benefits do users report?
A tighter waist, a leaner-looking midsection, maintained gym strength, and better sleep or recovery appear in the public accounts below. Some people reported these changes while scale weight stayed similar; others lost weight during a wider diet, training and peptide program.U1U2U3
| Reported benefit | What the accounts describe |
|---|---|
| Waist and appearance | A tighter midsection or smaller waist after several weeks.U1U2 |
| Gym performance | Maintained strength during a cut, or better workouts.U1U3 |
| Recovery and sleep | Perceived improvements alongside other treatments and lifestyle changes.U1U2U3 |
These are selected public first-person accounts, not verified customers or clinical outcomes. Identities, products and measurements were not independently verified; concurrent treatments prevent isolating tesamorelin’s contribution.
What results have real people described?
Three months: 185 lb to 169 lb, with strength maintained
COMPLETED COURSEA 29-year-old man reported losing 16 lb over three months, a leaner waist and lower abdomen, and maintained gym strength. His body-fat estimates changed from about 18% to 14%. He noticed physical changes around month two; earlier changes included better sleep and water retention. Context: tesamorelin with ipamorelin and creatine, a reported 500-calorie deficit, around 180 g protein daily, lifting twice weekly and triathlon training.U1
Seven weeks: a smaller waist and better recovery
POSITIVE & MIXEDA 45-year-old woman described leaning out, a smaller waist and improved recovery. Context: she also used retatrutide and later a tesamorelin/ipamorelin blend. The same account reported nighttime hand numbness and IGF-1 rising from 189 to 373 ng/mL. She was reassessing a planned 12-week course; this was a seven-week update, not a completed 12-week result.U2
Eight weeks: tighter midsection, unchanged scale weight
BODY COMPOSITIONOne poster described a tighter midsection and better gym performance while weight remained around 90.4 kg. Context: around 1,900 calories daily, five training days weekly, daily cardio and at least 10,000 steps. Follow-ups disclosed retatrutide, ipamorelin, GLOW and DSIP, plus a consistent 8–9-hour sleep schedule. The author also reported illness interruptions. These changes cannot be assigned to tesamorelin alone.U3
Twelve-week course: a lower reported DEXA fat estimate
SCAN FIGURES REPORTEDA forum participant reported a visceral-fat estimate of 201 cm² at week four and 136 cm² after a 12-week course—two scans eight weeks apart. Context: other posts described retatrutide, ipamorelin and a wider peptide regimen. The author also reported worsening insulin-resistance markers. These are the author’s scan and bloodwork descriptions; the comparison did not begin before treatment.U4
About two months: no visible or weight change
NO CHANGE REPORTEDAnother poster reported no visible improvement or scale-weight loss after roughly two months, despite regular gym sessions, increased protein and a reported 2,300 calories daily. A follow-up scan had not yet been posted. The account’s dose-conversion figures conflicted, so its actual exposure cannot be reconstructed reliably.U5
How quickly do users notice changes?
Several selected accounts describe changes around weeks seven to eight or month two. The completed three-month report placed its noticeable physical changes in month two. Another person reported no visible progress at roughly the same time.U1U2U3U5
The longer accounts provide later checkpoints: three months for the 16 lb weight change, and the end of a reported 12-week course for the second DEXA estimate. Those are individual updates, not a typical-result timetable.U1U4 The clinical sections below explain which effects have been measured under controlled conditions.
Which benefits are supported by clinical research?
Tesamorelin’s best-supported benefit is reducing visceral abdominal fat. Clinical studies also report improvements in belly appearance, some lipid measurements, and selected body-composition measures. The strongest evidence comes from adults with HIV-associated abdominal fat accumulation.1
| Outcome | What the evidence supports |
|---|---|
| Fat around abdominal organs | A demonstrated reduction in the pivotal trials.1 |
| General weight loss | The approved medicine is weight neutral and is not indicated for weight-loss management.2 |
| Muscle | Exploratory imaging findings in selected responders; no established healthy-bodybuilding result.4 |
| Liver fat | Positive results in a smaller trial involving HIV and fatty liver disease.5 |
Those outcomes answer different questions. A reduction in one fat compartment cannot be translated into a promised change in scale weight, visible abdominal definition, or gym performance.
How much visceral fat did people lose?
A pooled analysis of 806 participants reported a 15.4% treatment effect versus placebo after 26 weeks. Abdominal imaging measured visceral adipose tissue. The percentage does not mean a 15.4% reduction in body weight or whole-body fat percentage.1
In one of the original trials, visceral fat fell 15.2% from baseline with tesamorelin, while the placebo group increased 5.0%. These figures use a different comparison from the pooled 15.4% treatment effect; they should not be added together.3
Does it remove the fat you can pinch?
The pooled trials did not demonstrate a significant reduction in abdominal subcutaneous fat, the layer beneath the skin. This makes the type of abdominal fat a central part of the expected result.1
Can tesamorelin make the waist or stomach look smaller?
Abdominal appearance improved in the clinical studies. Participants and physicians rated belly profile more favorably, and participants reported less distress about its appearance.1
The prescribing information reports average waist changes of about 2–3 cm from baseline in the tesamorelin groups across the two pivotal studies, compared with approximately 1 cm in the placebo groups at 26 weeks. These are group averages with substantial individual variation.2
A visual change can therefore occur without substantial scale-weight loss. A photograph alone cannot show how much visceral fat changed: the trial measurement came from imaging. Claims such as “lose a fixed number of inches in four weeks” do not follow from these results.
Does tesamorelin build muscle?
There is a signal for improved muscle composition, but it comes from a selected study group. An exploratory analysis compared 193 tesamorelin responders with 148 placebo recipients. Responders had already achieved at least an 8% reduction in visceral fat; they were not all people originally assigned to tesamorelin.4
After 26 weeks, imaging showed increased density in several trunk muscle groups and increases in some muscle-area measurements. These findings support further research into muscle quality and quantity. They do not establish a predictable gain in strength, athletic performance, or new muscle tissue in healthy lifters.4
What this means for bodybuilding: the study cannot supply a reliable answer to “how many pounds of muscle will I gain?” Its selected population, imaging endpoints, and exploratory design are important limits. The dosage and cycle guide separates studied regimens from bodybuilding claims.
Does tesamorelin reduce fat in the liver?
Yes, in a specific clinical population. A 12-month randomized trial enrolled 61 people with HIV and fatty liver disease. The difference in hepatic fat fraction favored tesamorelin by 4.1 percentage points, corresponding to a 37% relative reduction in the study’s analysis.5
At 12 months, 35% of tesamorelin recipients had liver fat below the study’s 5% threshold, compared with 4% of placebo recipients. These are liver-imaging results, not percentages of total body fat lost.5
An earlier six-month randomized study also found a reduction in liver fat in adults with HIV and abdominal fat accumulation.8 The findings are promising, but neither trial establishes tesamorelin as a general treatment for every cause of fatty liver or proves that it prevents cirrhosis.
Has tesamorelin been studied outside the pivotal HIV trials?
Yes. A separate 12-month trial studied 60 adults with abdominal obesity and reduced growth-hormone secretion. Compared with placebo, tesamorelin reduced visceral fat and improved triglycerides and certain cardiovascular-risk markers. It did not significantly reduce abdominal subcutaneous fat.6
This is relevant evidence for a defined obesity subgroup. The participants were selected partly by their hormone testing, so the result cannot be assumed for every person with excess abdominal fat. It also does not establish fewer heart attacks, a broad obesity indication, or a standard fat-loss protocol for healthy athletes.
The distinction is practical: “studied in people with a specific condition” and “proven for anyone seeking a leaner waist” are different claims.
How long do benefits take, and what happens after stopping?
Measured fat reduction
The pivotal trials assessed their main visceral-fat outcome at approximately six months. That is the strongest reference point for the headline results.3
Benefit maintained
In an extension study, the group continuing treatment maintained an approximately 18% visceral-fat reduction from its original baseline.7
Visceral fat returned
Participants switched to placebo reaccumulated visceral fat. The study does not support a short course producing a permanent result.7
These timepoints do not tell us the first day a particular person will notice a change. An eight-week “cycle” and a 26-week clinical endpoint are different exposures. Continuing longer also brings continuing treatment burden, so response and tolerability both matter.
Can women benefit, and does tesamorelin raise testosterone?
The approved adult indication is not restricted to men. Women were included in the pivotal research, although one major trial was 86% male. That limits the precision of women-only conclusions drawn from the overall average.23
Tesamorelin targets the growth-hormone pathway. Its trials do not establish a dependable testosterone increase, and it is not a testosterone-replacement treatment. A rise in IGF-1 should not be interpreted as proof that testosterone rose or that more hormone elevation means more benefit.2
Pregnancy is a contraindication. The side-effects and safety guide covers pregnancy, glucose, IGF-1, and other factors that affect whether treatment is suitable.2
Tesamorelin benefits FAQ
Will tesamorelin give me visible abs?
No study can promise that result. Visceral-fat changes and visible muscle definition are different outcomes; the pivotal trials did not establish a significant reduction in the abdominal fat layer under the skin.1
Does it work only if body weight falls?
No. The medicine’s approved labeling describes a weight-neutral effect. Body weight and the size of a particular fat compartment are separate measurements.2
Are the liver-fat figures the same as belly-fat figures?
No. The liver study measured hepatic fat fraction. Its 37% relative reduction should not be reused as a claim about total body fat, waist size, or visceral fat.5
Can a short course permanently remove visceral fat?
That has not been demonstrated. Withdrawal follow-up showed fat reaccumulation after tesamorelin was stopped.7
Sources for the community accounts
- U1Three-month tesamorelin/ipamorelin report.
- U2Seven-week body-composition and IGF-1 report.
- U3Eight-week appearance and weight report.
- U4Twelve-week DEXA account.
- U5Two-month no-change report.
Sources for the benefits and research
- 1Falutz et al. Pooled phase III trials. Visceral fat and abdominal appearance in 806 participants.
- 2EGRIFTA WR prescribing information. Indication, clinical measurements, contraindications and hormone effects.
- 3Falutz et al. Randomized visceral-fat trial. Twenty-six-week outcomes and the studied population.
- 4Muscle area and density analysis. Exploratory findings among selected tesamorelin responders.
- 5Stanley et al. Liver-fat trial. Twelve-month randomized study in HIV and fatty liver disease.
- 6Makimura et al. Obesity and reduced GH secretion. Twelve-month randomized trial involving 60 adults.
- 7Falutz et al. Treatment extension and withdrawal. Maintenance of benefit and fat reaccumulation after stopping.
- 8Stanley et al. Visceral and liver-fat study. Six-month randomized trial in adults with HIV.